Artelo Biosciences Inc(ARTL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:10 AM ET (Korea 9/30 20:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -206.84 | Insider Own | 0.06% | Shs Outstand | 0.6M | Perf Week | -1.93% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | -31.76% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 2.38% | Short Float | 4.1% | Perf Quarter | -59.62% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.05 | Perf Half Y | -94.82% |
| Sales | 0.00B | P/B | 0.38 | EPS next 5Y | - | ROA | -234.3% | Short Interest | 0.02M | Perf YTD | -87.64% |
| Book/sh | 10.74 | P/C | 0.53 | EPS past 3/5Y | 16.31% 35.6% | ROE | -705.71% | 52W High | -97.73% ($179.19) | Perf Year | -97.42% |
| Cash/sh | 7.65 | P/FCF | - | Sales past 3/5Y | - | ROIC | -253.22% | 52W Low | 17.97% ($3.45) | Perf 3Y | -98.28% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 59.79% | Gross Margin | - | Volatility(W/M) | 69.3% 26.07% | Perf 5Y | -99.79% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3 | EPS Q/Q | 94.68% | Profit Margin | - | RSI (14) | 40.82 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3 | Sales Q/Q | - | SMA20 | -21.49% ($5.18) | Beta | -0.09 | Target Price | $486 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -35.61% ($6.32) | Rel Volume | 0.19 | Prev Close | $4.3 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -84.49% ($26.24) | Avg Volume(3M) | 0.48M | Price | $4.07 |
| IPO | 2017/11/14 | Option/Short | No/Yes | Trades | 806 | Volume | 88,960 | Change | -5.35% |
🧪 This is a clinical-stage biotech developing novel drugs that modulate lipid signaling pathways (including the endocannabinoid system). It is a micro-cap stock with a multi-pronged pipeline targeting areas of significant unmet medical need — including pain, cancer-related anorexia, glaucoma, anxiety, inflammation, and skin disorders.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual That is 19% of its average volume.
ARTL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +76% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #585 of 592 in the industry
Based on market cap of $2M.
PPBT#582 Purple Biotech Ltd ADR $2M PER - 
LABT#583 Lakewood-Amedex Biotherapeutics Inc $2M PER - 
GNPX#584 Genprex Inc $2M PER - ARTL#585 Artelo Biosciences Inc $2M PER - 
OGEN#586 Oragenics Inc $2M PER - 
FAQ
What kind of company is ARTL?
ARTL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARTL?
The market cap of ARTL is approximately $2M, ranking 5,835 within its sector.
What is the 52-week high and low for ARTL?
ARTL has recorded a 52-week high of $179.19 and a low of $3.45.
